Gilead Sciences
In the news
Would homegrown LEN cost more? Why SA should still make the HIV prevention jab
South Africa aims to manufacture the revolutionary six-monthly HIV prevention injection lenacapavir locally. Experts weigh the need for rapid, affordable access against building…
Video
SA and Zambia’s HIV shot dilemma: Demand versus supply
South Africa and Zambia are grappling with a significant challenge in rolling out lenacapavir, a new six-monthly HIV prevention injection. Despite high demand and promising early…
#Aids2026: Bhekisisa analysed SA’s first LEN roll-out data. Here's what it found
South Africa accounts for over half of all lenacapavir (LEN) users in Africa, with health department data revealing 31,297 of the continent's roughly 60,000 users are in the…
#Aids2026: Daily pill. Monthly pill. Six-monthly jab. Why choice matters
For the first time, Merck has granted generic manufacturers, including three African companies, permission to produce an investigational monthly HIV prevention pill, alimatravir,…